Martin Auster is CFO at Ventyx Biosciences, Inc. (VTYX). They have made 8 open-market trades across 1 company since 2022, most recently 2024-04-02.
CIK 0001875786
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VTYX | 24,303 | $340K |
Shares reported on the most recent Form 4, priced at the 2024-04-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VTYX | SELL | 2024-04-02 | 2024-04-03 | $5.40 | $8K | -8.1% | -4.5% | -57.9% |
| VTYX | SELL | 2023-09-05 | 2023-09-07 | $32.61 | $1.7M | +12.7% | -10.0% | -93.5% |
| VTYX | SELL | 2023-07-25 | 2023-07-26 | $35.54 | $995K | -9.6% | -14.0% | -56.9% |
| VTYX | SELL | 2023-06-06 | 2023-06-07 | $34.64 | $1.9M | -6.6% | -1.1% | -8.8% |
| VTYX | SELL | 2023-04-25 | 2023-04-27 | $38.03 | $2.1M | +8.0% | -6.5% | -0.1% |
| VTYX | SELL | 2023-04-17 | 2023-04-19 | $33.00 | $231K | +7.9% | -4.6% | -0.6% |
| VTYX | SELL | 2023-04-04 | 2023-04-05 | $30.76 | $1.3M | +28.6% | +38.7% | +32.7% |
| VTYX | SELL | 2022-12-02 | 2022-12-06 | $29.01 | $5.7M | +20.0% | +12.6% | +61.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.